Vizgen, Inc. and Hamamatsu Photonics K.K. Partner to Streamline Spatial Biology Workflows

Published: 2025-05-29 15:20:33 ET 6965.T

Published on 05/29/2025 at 15:20

Vizgen, Inc. announced a strategic partnership with Hamamatsu Photonics K.K. This collaboration integrates Hamamatsu's MoxiePlex?? multiplex immunofluorescence (mIF) imaging system with Vizgen's pathology-grade reagent and assay portfolio, delivering a seamless end-to-end solution designed to bring multiplexed biomarker detection into new translational and clinical research applications. The partnership aims to eliminate common barriers in multiplex assay development streamlining validation, simplifying workflow integration, and enabling researchers to focus on acquiring high-fidelity biological insights.

By combining cutting-edge imaging with highly adaptable multiplex assays, this partnership will offer a joint solution designed to scale with customer needs and facilitate the transition from research to clinical impact. The MoxiePlex?? platform offers up to 9-color imaging with high throughput capacity with up to 60 slides per run designed for high-volume laboratories.

Vizgen's InSituPlex®? assays enable rapid deployment of custom research panels with pre-validated biomarkers, minimizing time-to-data while maintaining exceptional specificity and reprodu reproduibility. Together, these technologies empower research labs to build and refine multiplex assays with greater speed and confidence.

Vizgen and Hamamatsu plan to combine their expertise through validated InSituPlex panels, coupled with MoxiePlex, as an integrated multiplexed proteomic biomarker offering capable of multi-site deployments for translational research and clinical research applications. Among the first use cases for this integrated solution is the deployment of mIF panels for clinically relevant research on non-small cell lung cancer (NSCLC) specimens.